JAMA Impact Factor

Among Medicine, General & Internal journals, JAMA ranks in the top 1% by impact factor (JCR 2024). This ranking is based on our analysis of 20,449 journals in the Clarivate JCR 2024 database.

The 2021-2022 spike was driven almost entirely by heavily cited COVID-19 research. JAMA published landmark pandemic studies that accumulated citations at an extraordinary rate. The 2024 JIF of 55 has decreased from the pandemic-era peak of 157 in 2021, returning to the journal's structural baseline. The pre-pandemic trajectory (2017-2019 average: ~48) puts the current level in historical context: JAMA's citation position is meaningfully stronger than it was before COVID amplified general medical journal citations.

JAMA's current JIF belongs to the same long-running pattern: it remains one of the most cited and most visible general-clinical journals in the world. The exact annual number moves around, but the underlying position is stable. JAMA is not a journal that briefly spiked because of one trend cycle and then slipped back into the middle of the pack. It operates in the top tier of general medicine every year because it publishes work that reaches physicians across specialties, not just one field.

That distinction matters when authors compare JAMA with strong specialty journals. A specialty cardiology or oncology title may be the right home for your paper even if JAMA's raw number is much higher, because JAMA's citation strength comes from breadth. The number reflects cross-specialty reach, clinical relevance, and broad editorial visibility.

So the trend takeaway is straightforward: JAMA's impact factor is not a curiosity. It is consistent with the journal's role as a general-clinical gatekeeper.

It also helps explain why JAMA is searched so often by authors deciding between top clinical brands. Researchers are not only asking whether the journal is prestigious. They are asking whether it sits closer to NEJM and The Lancet than to strong specialty journals. On citation position alone, the answer is clearly yes. On manuscript fit, the answer depends much more on breadth, consequence, and audience.

Scopus metrics complement the JCR impact factor by using different citation windows and weighting methods. CiteScore covers four years instead of two, while SJR weights citations from high-prestige journals more heavily. For a journal like JAMA, it's worth checking whether both systems agree.

JAMA's SJR of 5.352 is among the highest in general medicine, and its SNIP of 10.710 confirms that the journal's influence isn't just an artifact of medicine's high baseline citation rates. Both metrics tell the same story as the JCR impact factor: JAMA sits firmly in the elite tier.

It gives you a useful read on JAMA's citation position and audience reach.

• JAMA articles tend to be read and cited well beyond one subspecialty.
• The journal sits in a part of medicine where publication can influence clinical discussion, policy conversation, and career signaling at the same time.
• A paper that lands here is likely to be seen by a broad physician audience rather than a narrow expert circle.
• The journal's visibility is strong enough that even people outside your immediate field will recognize the placement.

If your goal is maximum specialist recognition inside one discipline, that is a different question. But if you want to understand JAMA's citation weight, 55 answers that cleanly.

• whether your manuscript actually fits the journal
• how likely the editor is to desk reject
• how long peer review will take
• how your specific paper will perform after publication

The missing fit question is especially important with JAMA. Plenty of very strong clinical papers are better matches for specialty venues because their main consequence stays inside one disease area. JAMA does not reward specialty importance alone. It rewards work that feels broadly relevant to practicing physicians, clinical policy, or public-health decision-making.

If you are trying to decide whether JAMA is realistic, the impact factor is less important than the editorial bar.

• Broad clinical consequence. Editors want a paper that changes how doctors think or act, not just a careful study with positive results.
• General-medicine readability. A paper that only makes immediate sense to one subspecialty reviewer usually feels too narrow.
• Outcome relevance. Hard clinical endpoints, practice implications, and health-system consequences carry more weight than surrogate-only stories.
• Clean framing from the first paragraph. If the importance of the study takes too long to emerge, the paper becomes easier to reject early.

That is why JAMA traffic often needs routing into deeper decision pages. If you are evaluating fit rather than just prestige, the next useful pages are usually the full JAMA journal profile, the JAMA fit guide, and the JAMA desk-rejection page.

Through our JAMA submission readiness check, we've reviewed manuscripts targeting JAMA and other top general medical journals. JAMA has one of the most distinctive editorial cultures in medicine, and understanding it changes how you should prepare your submission.

JAMA's structured abstract format (Importance, Objective, Design, Setting, Participants, Main Outcomes, Results, Conclusions) is not optional decoration. It's the editor's triage tool. We regularly see manuscripts where the "Importance" field is weak or generic ("Cardiovascular disease is a leading cause of death..."). That's wasted space. The strongest JAMA submissions use the Importance field to name a specific clinical uncertainty that the study resolves. Editors read hundreds of submissions per week and make desk decisions in days; generic framing gets filtered immediately.

JAMA accepts approximately 5% of submissions and has one of the most aggressive desk rejection rates in medicine. The JAMA Network of 13 specialty journals (JAMA Internal Medicine, JAMA Oncology, JAMA Cardiology, etc.) exists partly to redirect strong specialist work that isn't broad enough for the flagship. If your paper speaks primarily to one clinical specialty, JAMA editors may suggest a Network journal before you even reach review. This is not a rejection; it's editorial routing. Many authors misread it as failure.

The statistical review at JAMA is notably rigorous. JAMA employs dedicated statistical reviewers who check analysis plans, effect sizes, and reporting completeness independently of the scientific reviewers. Issues we commonly flag: underpowered secondary analyses presented as primary findings, missing pre-registration documentation for clinical trials, and confidence intervals that don't support the conclusions in the abstract.

The common mistake is simple: authors see a number this high and conclude that JAMA is the "better" target than a specialty journal with a lower JIF. In practice, the better target is the journal that will judge your paper on the right criteria.

A strong specialty cardiology paper can be more competitive at a top cardiology journal than at JAMA. A narrow but excellent oncology paper can belong in a field-leading cancer journal without losing strategic value. For many authors, that is the real lesson of the JAMA number: the bar is not just quality. It is quality plus breadth.

That is also why high-impact pages need to route into conversion-oriented decision pages. The number may win the impression, but the fit decision determines whether the reader becomes a qualified lead.

If you remember only one submission lesson from this page, make it this one: a lower-JIF journal that evaluates your paper on the right editorial criteria is often the strategically stronger choice than a higher-JIF journal that will reject it in editorial triage.

The IF of 55 is what everyone searches for, but JAMA's JCR profile has more to say. These metrics paint a fuller picture of how the journal actually performs in the citation ecosystem.

The JCI of 7.94 deserves attention. It means JAMA papers are cited roughly 8 times more than the average paper in general medicine. That's not just prestige, it's structural reach. The 5-year JIF running higher than the 2-year (64.7 vs. 55) shows JAMA papers don't peak and fade. They accumulate citations over time, which is characteristic of papers that become reference points for clinical practice and policy.

All four "big general medicine" journals publish clinical trials and broad-audience medical research. But they're not interchangeable, and the editorial identity differences matter for submission strategy.

Submit if:

• the finding changes a clinical decision, a prescribing practice, or a public health recommendation, and you name the change explicitly
• the study has implications that cross specialty lines and would matter to physicians across disciplines
• the research addresses health equity, health policy, or healthcare delivery in the US context
• the methods are definitive (well-powered RCT, large well-designed observational study, rigorous meta-analysis)

Think twice if:

• the primary audience is a specialty rather than general medicine (consider JAMA Cardiology, JAMA Oncology, JAMA Neurology, etc.)
• the study advances a scientific understanding without a named clinical or policy implication
• the research was conducted in a single center or a single country context without a generalizable conclusion
• the endpoint is a surrogate marker without demonstrated connection to patient outcomes

A JAMA readiness check can assess whether the significance framing, clinical impact language, and abstract structure read as a JAMA paper or a specialty journal paper.

JAMA's real niche is research that speaks to the American medical system, health policy, disparities, public health, and medical education. If your paper addresses how medicine is practiced, taught, or delivered in the US, JAMA's editors will read it differently than NEJM's would. NEJM wants practice-changing efficacy data. Lancet wants global health framing. JAMA wants work that matters to the physician as both a clinician and a citizen. That's a real editorial distinction, not marketing.

In our pre-submission review work on manuscripts targeting JAMA, three patterns account for most of the desk rejections we see.

Technically sound clinical studies where the significance framing stops at the science rather than reaching the clinical decision. JAMA's stated focus is research that helps readers "make better decisions", the practical endpoint is a physician, public health official, or policy maker changing what they do. The documented desk rejection pattern is not that the science is weak; it is that the paper's significance is framed in scientific terms rather than clinical or decision terms. A well-powered randomized trial that shows a statistically significant effect on a surrogate endpoint, without explaining what practice should change as a result, is a routine JAMA desk rejection even when the methods are excellent. The standard is whether the paper changes a clinical decision, not whether it confirms a mechanistic hypothesis. Authors who write significance sections for an academic science audience rather than for a physician-reader audience consistently miss this threshold.

Specialty-specific findings submitted without general medicine framing. JAMA is a general medicine journal with approximately 80% desk rejection rate, and one of the primary rejection triggers is papers that are appropriate for a JAMA specialty journal (JAMA Cardiology, JAMA Oncology, JAMA Neurology, etc.) but submitted to the main journal. A trial in atrial fibrillation management, a study of immunotherapy biomarkers in lung cancer, or a neurocognitive outcome study in stroke are not inherently JAMA main journal papers even when the results are strong. The editorial question is whether the finding has implications for physicians across specialties, not just for cardiologists, oncologists, or neurologists. Papers that affect how any physician thinks about a clinical problem (diagnostic reasoning, prescribing patterns, health system design) read as JAMA papers. Papers that primarily advance a specialty's evidence base belong in the specialty journal where the exact readership is concentrated.

Studies that document a problem without connecting to implementation, equity, or system-change implications. JAMA's editorial priorities are documented as favoring research connected to implementation, health equity, or cost implications, findings where the next step is a policy, system, or practice change that is named and feasible. We see well-designed observational studies that characterize a clinical phenomenon or health disparity accurately and rigorously, but without a sentence in the paper that a health minister, a hospital system, or a payer could act on. JAMA publishes epidemiology, but the standard is that the epidemiology connects to something actionable in the health system. A study that shows a disparity exists is valuable; a study that shows a disparity exists, explains why, and identifies an intervention point is the JAMA paper. The distinction is not optimism about solutions but specificity about implications.